Company intelligence / Profile preview

IM Therapeutics

Boston, Massachusetts, United Statesimtherapeutics.com ↗

Ownership: Private
Development stage: Phase 1

Overview

IM Therapeutics has developed a personalized oral small molecule therapy targeting the HLA-DQ8 protein to prevent immune-mediated destruction of insulin-producing beta cells in type 1 diabetes. Their lead candidate, IMT‑002 (D-methyldopa), has received Orphan Drug Status from the FDA and entered Phase I clinical trials in mid‑2020. The company’s approach aims to address high unmet needs in T1D and celiac disease by blocking key genetic drivers of autoimmunity. Initial results focus on safety and pharmacodynamics; further data pending.

Therapeutic areas: GastroenterologyEndocrinologyImmunology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

D-methyldopa

Beyond the preview

Go deeper on IM Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IM Therapeutics.

Explore the full profile